IRCT20200623047902N8Completed未知
Bioequivalence study of Azithromycin 250 mg capsule manufactured by Sanamed company versus the originator brand in healthy volunteers
Sanamed pharma company0 sites24 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 24
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 55 years (—)
- Sex
- All
Inclusion Criteria
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
Exclusion Criteria
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Azithromycin
Investigators
Similar Trials
Completed
Not Applicable
Bioequivalence study of Azithromycin 500 mg tabletThis study is performed on healthy volunteers..IRCT20200623047902N13Sanamed pharma company24
Not yet recruiting
Unknown
Bioequivalence evaluation of Azithromycin Capsule 500 mg of Mahban Pharmaceutical companyIRCT20200625047913N15Hezareh Sevom Futuristic Pharmacist24
Not yet recruiting
Not Applicable
Bioequivalence evaluation of Azithromycin Capsule 500 mg/ Suspension 200 mg/5 ml manufactured by Dora Darou company-.IRCT20200625047913N3Hezareh Sevom Futuristic Pharmacist24
Not yet recruiting
Not Applicable
Investigating the in vivo bioequivalence of Azithromycin 250 mg capsuleIRCT20210519051345N13Tabriz University of Medical Sciences24
Completed
Not Applicable
Bioequivalence study of Azithromycin 200 mg/5mL powder for oral suspension in healthy Thai volunteer under fasting conditioTCTR20180109003All Research Co., Ltd.42